We assessed the effectiveness of
iloprost treatment in the management of symptomatic
Buerger disease (BD) and assessed smoking cessation compliance, based on a single-center experience. Thirteen patients with BD were treated with sessions of intravenous (IV) Ilomedin infusion. At 1-year follow-up,
pain status alteration, number of
analgesics required, ankle-brachial index (ABI) change, compliance with supervised smoking cessation, and
amputation-free rate were recorded. The
pain status improved considerably according to a visual analog scale, the number of
analgesics required was significantly reduced, and all patients improved their
pain-free walking distance, the ABI, and their self-reported quality of life. Only 2 patients required minor
amputations. Combination of IV Ilomedin infusion, supervised smoking cessation, and a specific follow-up protocol may lead to improvement in
pain-free walking distance,
pain status, quality of life, and substantial reduction in
amputation risk.